Evofem Biosciences, Inc. (EVFM): Price and Financial Metrics
GET POWR RATINGS... FREE!
EVFM POWR Grades
- Growth is the dimension where EVFM ranks best; there it ranks ahead of 53.49% of US stocks.
- EVFM's strongest trending metric is Growth; it's been moving up over the last 154 days.
- EVFM's current lowest rank is in the Quality metric (where it is better than 0.5% of US stocks).
EVFM Stock Summary
- EVFM's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 4.25% of US stocks.
- Revenue growth over the past 12 months for Evofem Biosciences Inc comes in at 1,748.43%, a number that bests 99.43% of the US stocks we're tracking.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for EVFM comes in at -132.07% -- higher than that of only 2.79% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Evofem Biosciences Inc are DTSS, MDGS, NBRV, AQB, and RWLK.
- Visit EVFM's SEC page to see the company's official filings. To visit the company's web site, go to www.evofem.com.
EVFM Valuation Summary
- In comparison to the median Healthcare stock, EVFM's price/sales ratio is 255.95% higher, now standing at 40.4.
- EVFM's price/sales ratio has moved NA NA over the prior 83 months.
- EVFM's price/sales ratio has moved NA NA over the prior 83 months.
Below are key valuation metrics over time for EVFM.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| EVFM | 2021-08-31 | 40.4 | 15.4 | -0.9 | -1.0 |
| EVFM | 2021-08-30 | 35.7 | 13.6 | -0.8 | -0.9 |
| EVFM | 2021-08-27 | 36.4 | 13.8 | -0.8 | -0.9 |
| EVFM | 2021-08-26 | 36.2 | 13.8 | -0.8 | -0.9 |
| EVFM | 2021-08-25 | 37.8 | 14.4 | -0.9 | -1.0 |
| EVFM | 2021-08-24 | 32.7 | 12.4 | -0.7 | -0.9 |
EVFM Growth Metrics
- Its 5 year cash and equivalents growth rate is now at -61.86%.
- Its 3 year net cashflow from operations growth rate is now at -13.08%.
- The 3 year price growth rate now stands at -20.25%.
The table below shows EVFM's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-12-31 | 8.244 | -146.667 | -206.239 |
| 2021-09-30 | 4.842 | -164.481 | -194.236 |
| 2021-06-30 | 3.408 | -162.936 | -150.074 |
| 2021-03-31 | 1.551 | -124.411 | -169.314 |
| 2020-12-31 | 0.446 | -104.829 | -142.309 |
| 2020-09-30 | 0.278 | -79.196 | -114.428 |
EVFM's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- EVFM has a Quality Grade of F, ranking ahead of 0.28% of graded US stocks.
- EVFM's asset turnover comes in at 0.032 -- ranking 346th of 682 Pharmaceutical Products stocks.
- AGRX, EVOK, and ARMP are the stocks whose asset turnover ratios are most correlated with EVFM.
The table below shows EVFM's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.032 | 0.468 | -3.756 |
| 2021-03-31 | 0.014 | 0.372 | -6.609 |
| 2020-12-31 | 0.005 | -0.049 | -10.499 |
| 2020-09-30 | 0.004 | -0.140 | -65.377 |
| 2020-06-30 | 0.000 | NA | 23.332 |
| 2020-03-31 | 0.000 | NA | 10.597 |
EVFM Price Target
For more insight on analysts targets of EVFM, see our EVFM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $8.40 | Average Broker Recommendation | 1.5 (Moderate Buy) |
EVFM Stock Price Chart Interactive Chart >
EVFM Price/Volume Stats
| Current price | $0.41 | 52-week high | $14.61 |
| Prev. close | $0.46 | 52-week low | $0.28 |
| Day low | $0.40 | Volume | 3,406,612 |
| Day high | $0.46 | Avg. volume | 14,850,388 |
| 50-day MA | $0.73 | Dividend yield | N/A |
| 200-day MA | $4.33 | Market Cap | 5.02M |
Evofem Biosciences, Inc. (EVFM) Company Bio
Evofem Biosciences, formerly Neothetics, develops and anticipates commercializing innovative products to address unmet needs in women's sexual and reproductive health. Its lead candidate is Amphora, a non-hormonal, surfactant-free bioadhesive vaginal gel designed for on-demand use as needed or desired by a woman. This investigational new drug is being developed as an on-demand, non-hormonal vaginal contraceptive and for the prevention of certain sexually transmitted infections (STIs). Data from a confirmatory Phase 3 clinical trial of Amphora for the prevention of pregnancy are expected in late 2018/early 2019. A Phase 2b/3 clinical trial of Amphora for the prevention of urogenital chlamydia and gonorrhea in women is also underway. Amphora received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the prevention of urogenital chlamydia in women, and is designated as a Qualified Infectious Disease Product (QIDP) by the U.S. Food & Drug Administration for the prevention of urogenital gonorrhea infection in women. The Company's second multipurpose prevention technology (MPT) vaginal gel candidate has QIDP designation for the reduction of reoccurrence of bacterial vaginosis. These designations may enable Evofem Biosciences to more rapidly evaluate and make these drugs available to women at risk of these infections.
Latest EVFM News From Around the Web
Below are the latest news stories about Evofem Biosciences Inc that investors may wish to consider to help them evaluate EVFM as an investment opportunity.
Evofem Biosciences to Report Fourth Quarter and Year-End 2021 Results and Provide Corporate Update on Thursday, March 3, 2022Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the fourth quarter and year ended December 31, 2021 on Thursday, March 3, 2022 at 4:30 p.m. ET (1:30 p.m. PT). |
FDA Awards QIDP Designation for Prevention of Chlamydia to Evofem BiosciencesEvofem Biosciences, Inc., (NASDAQ: EVFM) announced today that the U.S. Food and Drug Administration (FDA) has awarded "Qualified Infectious Disease Product" (QIDP) Designation to EVO100 (the investigational name for Phexxi® (lactic acid, citric acid and potassium bitartrate)) for the prevention of urogenital chlamydia infection in women, a potential new indication in late stage clinical development. Chlamydia is the most frequently reported bacterial infection in the United States. |
Evofem Biosciences to Present at Aegis Virtual Conference on Wednesday, February 23, 2022Evofem Biosciences, Inc., (NASDAQ: EVFM) will present at the Aegis Virtual Conference as follows: |
Callan Capital, LLC Buys Schwab Fundamental U.S. ...La Jolla, CA, based Investment company Callan Capital, LLC (Current Portfolio) buys Schwab Fundamental U.S. |
Evofem Biosciences Announces Record Net Sales and Phexxi Prescriptions in Q4 2021Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced strong preliminary results for the fourth quarter of 2021, including record growth in net product sales of its hormone-free prescription contraceptive gel, Phexxi® (lactic acid, citric acid and potassium bitartrate). |
EVFM Price Returns
| 1-mo | -64.35% |
| 3-mo | -64.04% |
| 6-mo | -93.44% |
| 1-year | -96.42% |
| 3-year | -99.49% |
| 5-year | -98.80% |
| YTD | -92.72% |
| 2021 | -84.42% |
| 2020 | -60.94% |
| 2019 | 47.26% |
| 2018 | -64.19% |
| 2017 | 74.11% |
Loading social stream, please wait...